Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths
Traws Pharma said it will advance clinical candidates for hantavirus after a cruise-ship outbreak killed three people, with no lead drug named yet. WHO confirmed five hantavirus cases on the MV Hondius, three fatal, and said person-to-person spread is limited. Traws shares jumped 21.8% after the announcement. The company has no approved products and recently raised $10 million in private funding.